Suven Pharmaceuticals Limited

NSE SUVENPHAR.NS

Suven Pharmaceuticals Limited Debt to Equity Ratio for the year ending March 31, 2024: 0.03

Suven Pharmaceuticals Limited Debt to Equity Ratio is 0.03 for the year ending March 31, 2024, a -21.81% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Suven Pharmaceuticals Limited Debt to Equity Ratio for the year ending March 31, 2023 was 0.04, a -36.26% change year over year.
Suven Pharmaceuticals Limited Debt to Equity Ratio for the year ending March 31, 2022 was 0.06, a -47.50% change year over year.
Suven Pharmaceuticals Limited Debt to Equity Ratio for the year ending March 31, 2021 was 0.12, a -45.05% change year over year.
Suven Pharmaceuticals Limited Debt to Equity Ratio for the year ending March 31, 2020 was 0.22, a 57.16% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

NSE: SUVENPHAR.NS

Suven Pharmaceuticals Limited

CEO	Dr. Sudhir Kumar Singh Ph.D.
IPO Date	March 9, 2020
Location	India
Headquarters	# 8-2-334, SDE Serene Chambers
Employees	1,193
Sector	Healthcare
Industries Chemicals & Advanced Materials Biotechnology Clinical Trials Petrochemicals Pharmaceuticals

Description

Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was incorporated in 2018 and is headquartered in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.

Key trends

Past 5 years